We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 15, 2021

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study
J. Clin. Oncol 2021 May 04;[EPub Ahead of Print], CAM Stege, K Nasserinejad, E van der Spek, YM Bilgin, A Kentos, M Sohne, RJW van Kampen, I Ludwig, N Thielen, N Durdu-Rayman, NCHP de Graauw, NWCJ van de Donk, EGM de Waal, MC Vekemans, GJ Timmers, M van der Klift, S Soechit, PAF Geerts, MH Silbermann, M Oosterveld, IS Nijhof, P Sonneveld, SK Klein, MD Levin, S Zweegman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading